Most of these events were gastrointestinal-related and included constipation, vomiting, diarrhea and nausea, and were more pronounced during the initial phase of treatment, particularly during dose escalation, and settled over time, Moiz said
weight loss
In this population: Higher waist-to-hip ratio increased risk up to 7.7-fold (especially peri-menopausally) Greater body fat percentage, waist-height ratio, or visceral fat area each increased risk around 4-fold Higher body mass index (BMI) or waist circumference, each, increased risk almost 3-fold Because obesity is associated with significant changes in immunometabolic and hormonal parameters, it seems likely that the strength of these findings will be confirmed in other populations
Discontinuation of tirzepatide typically results in weight regain, emphasising that this is a long-term therapeutic intervention rather than a short-term solution
La pldora de orforglipron, llamada Foundayo, es fabricada por Eli Lilly, que tambin comercializa los medicamentos GLP-1 Zepbound para la obesidad y Mounjaro para la diabetes
